Verus Capital Partners’s AMAG Pharmaceuticals AMAG Stock Holding History

Verus Capital Partners’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,000	Closed	-$12K	–	1636
2019 Q4	$12K	Buy	+1,000	New	+$10.9K	﹤0.01%	1064

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Verus Capital Partners's AMAG Position: Q1 2020 in Review

Verus Capital Partners sold out of AMAG Pharmaceuticals (AMAG) in Q1 2020, closing a stake of 1,000 shares — an estimated $12K sold.

Verus Capital Partners first reported a position in AMAG in Q4 2019 and held it in 1 quarter. The position peaked at $12K in Q4 2019. 119 funds tracked by Wall St. Rank hold AMAG as of Q1 2020.

Verus Capital Partners reported no remaining AMAG Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Verus Capital Partners sold 1,000 AMAG Pharmaceuticals shares in Q1 2020, an estimated $12K.
Verus Capital Partners first reported a position in AMAG Pharmaceuticals in Q4 2019 and held it in 1 quarter.
Verus Capital Partners's AMAG Pharmaceuticals position peaked at $12K in Q4 2019.
119 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.